Abstract:Inherited genetic disorders are progressive in nature and lead to organ dysfunction or death in severe cases. At present, there are no permanent treatment options for >95% of inherited disorders. Different modes of inheritance, type of gene(s) involved, and population-based variations add further complexity to finding suitable cures for approximately 400 million patients worldwide. Gene therapy is a very promising molecular technique for the treatment of rare genetic disorders. Gene therapy functions on the basis of restoration, replacement, inhibition, and, most recently, editing of gene(s) to rescue the disease phenotype. Recent reports show that increasing numbers of gene therapy clinical trials are using viral vectors (64.2%) when compared with non-viral vectors. Rapid development of efficient viral vector systems like the adeno-associated virus (AAV) and lentivirus has significantly contributed to this progress. Notably, AAV-mediated gene therapy has shown high potential for genetic disease treatment as evident from recent clinical trials for the eye (NCT00999609), blood (NCT00979238), and neuro-muscular systems (NCT02122952). Safety and efficacy are the two most critical features required for vector(s) to qualify for pre-clinical and clinical trial approval. The process of clinical-grade vector production, evaluation, and approvals for gene therapy products requires significant technological development, knowledge enhancement, and large financial investments. Additionally, trained manpower is required to meet the demands for constant technical innovation. These factors together contribute towards exorbitant prices for every dose of a gene therapy product and thus pose a challenge for the gene therapy field. The Indian subcontinent has traditionally lagged behind North America, Europe, Japan, and others in gene therapy clinical trials due to factors like inadequate industrial-scientific infrastructure, lack of accessible and organized patient databases, low financial investments, etc. However, over the last decade, increasing awareness of rare diseases, and international approvals of gene therapies such as Luxturna, Zolgensma, Hemgenix, etc., have spurred gene therapy development in India as well. In view of these advances, this article outlines gene therapy research, regulatory processes, and the launch of gene therapy clinical trials in India in the context of major developments worldwide. We briefly describe ongoing gene therapy research across Indian organizations and the nascent gene therapy product manufacturing. Further, we highlight the various initiatives from the medical and patient community to avail rehabilitation and gene therapy options. We briefly discuss the roles of regulatory agencies and guidelines for gene therapy clinical trials in India. We anticipate that this concise review will highlight the promise of gene therapy for the large population of rare disease patients in India.

Emerging opportunities for gene editing therapies in India

Rare genetic disorders in India: Current status, challenges, and CRISPR-based therapy

Recent developments in gene therapy research in India

CRISPR/Cas9-mediated genome editing: from basic research to gene therapy

Genome editing for crop improvement: A perspective from India

Advancing genome editing with artificial intelligence: opportunities, challenges, and future directions

Economic Viability of Cutting-Edge Genetic Treatments: Balancing Innovation and Fiscal Sustainability in India's Healthcare Sector

Making gene editing accessible in resource limited environments: recommendations to guide a first-time user

Current landscape of gene‐editing technology in biomedicine: Applications, advantages, challenges, and perspectives

Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders

Advances in CRISPR/Cas systems-based cell and gene therapy

CRISPR-Cas9 gene editing technology in human gene therapy: the new realm of medicine

Community health workers in India should be trained to offer genetic counselling for rare diseases

Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects

CRISPR and Gene Editing: A Game-Changer in Drug Development

CRISPR-Cas9 Gene Editing Therapy, a Curative Hope for Sickle Cell in Nigeria, West Africa

Recent Therapeutic Gene Editing Applications to Genetic Disorders

A comprehensive review on the current status of CRISPR based clinical trials for rare diseases

Gene therapy and gene editing strategies in inherited blood disorders

Hope, despair and CRISPR — the race to save one woman's life